APA (7th ed.) Citation

A, B., N, B., J, W., S, P., V, G., F, U., . . . S, L. (2021). AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms. HemaSphere, 5(9), e630. https://doi.org/10.1097/HS9.0000000000000630

Chicago Style (17th ed.) Citation

A, Beitzen-Heineke, et al. "AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms." HemaSphere 5, no. 9 (2021): e630. https://doi.org/10.1097/HS9.0000000000000630.

MLA (9th ed.) Citation

A, Beitzen-Heineke, et al. "AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms." HemaSphere, vol. 5, no. 9, 2021, p. e630, https://doi.org/10.1097/HS9.0000000000000630.